About This Trial
Next-generation mRNA vaccine targeting multiple Omicron subvariants with improved durability and broader protection.
Primary Endpoints
- Neutralizing antibody response
- Vaccine efficacy against symptomatic infection
Latest Update
February 2026
Interim analysis shows 78% efficacy against symptomatic infection. Strong T-cell responses observed across age groups.
Lead Investigators
DJ
Dr. Jacqueline Miller Senior VP, Infectious Disease Development